Morningstar

Eli Lilly 4Q Profit Rises as Weight-Loss Drug Demand Surges

Provided by Dow Jones

By Nicholas G. Miller 




  Eli Lilly reported higher fourth-quarter profit on the back of surging demand for its GLP-1 weight-loss drugs. 



  The pharmaceutical company reported net income of $6.64 billion, or $7.39 a share, up from $4.41 billion, or $4.88 a share, the year prior. 



  Adjusted earnings were $7.54 a share. Analysts polled by FactSet expected $6.91 a share. 



  Revenue rose 43% to $19.29 billion, driven by a 46% increase in volume, partially offset by a 5% decline in realized prices. Wall Street expected $17.94 billion in revenue. 



  The company has seen soaring demand for its weight-loss treatments Zepbound and Mounjaro, both of which saw sales more than double in the fourth quarter from the previous year. The company recorded $7.41 billion in Mounjaro revenue and $4.26 billion in Zepbound revenue. 



  Eli Lilly guided for 2026 revenue of $80 billion to $83 billion and earnings of $33.50 to $35 a share. Analysts see 2026 revenue of $77.64 billion and earnings of $32.47 a share. 



  Eli Lilly is also preparing to launch a new weight-loss pill called orforglipron. Analysts have said the convenience of the pill could spark even more demand than Zepbound and Mounjaro, which are injected weekly, as some patients are averse to injections. 





  Write to Nicholas G. Miller at nicholas.miller@wsj.com. 





  (END) Dow Jones Newswires



  February 04, 2026 07:27 ET (12:27 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for November
 
Plus, whether Microsoft, Alphabet, or Amphenol look attractive after earnings.  
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
This Once-Hot AI Stock Now Looks Deeply Undervalued
 
This chip stock looks cheap at a 30% discount, and its biggest growth years could still be ahead. 
 
 
William Kerwin, CFA 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
 
Historian Joseph Moore explores why a promising product can fail as an investment and why beating the market may not be worth the effort. 
 
 
Christine Benz and Amy C. Arnott, CFA 
 
 
 
3 of the Best Dividend Stocks to Own
 
These dividend stocks with economic moats offer durable payouts. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center